SCHEMBL966884

SCHEMBL966884

CNc1nc(N)nc(SCC(=O)Nc2cccc(C(F)(F)F)c2)c1C=O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.54
▸ LMNA P02545 6/20 0.54
▸ KMT2A Q03164 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ GAA P10253 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ SMN1; SMN2 Q16637 5/20 0.47
▸ TP53 P04637 4/20 0.47
▸ HTT P42858 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ PPARG P37231 1/20 0.47
▸ NCOA2 Q15596 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10327053 0.89 MAPT (0.55) MAPTLMNAKMT2ATSHRGAA
SCHEMBL963620 0.88 LMNA (0.52) MAPTLMNAKMT2ATSHRGAA
SCHEMBL965667 0.84 MAPT (0.51) MAPTLMNAKMT2ATSHRGAA
SCHEMBL964536 0.84 KMT2A (0.61) MAPTLMNAKMT2ATSHRGAA
SCHEMBL964028 0.81 LMNA (0.44) MAPTLMNAKMT2ATSHRGAA
SCHEMBL3460011 0.79 GRK2 (0.44) MAPTLMNAKMT2ATSHRGAA
SCHEMBL10327149 0.78 LMNA (0.53) MAPTLMNAKMT2ATSHRGAA
SCHEMBL965888 0.77 SMN1; SMN2 (0.51) MAPTLMNAKMT2AGAAKDM4E
SCHEMBL12947374 0.77 MAPT (0.52) MAPTLMNAKMT2ATSHRGAA
SCHEMBL964265 0.77 KMT2A (0.78) MAPTLMNAKMT2ATSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110021525-A1 P70S6 Kinase Modulators and Method of Use EXELIXIS, INC. (US) 2011-01-27 — — US claimed
EP-1678168-B1 P70S6 KINASE MODULATORS AND METHOD OF USE EXELIXIS INC (US) 2012-07-11 — — EP disclosed
US-20110021525-A1 P70S6 Kinase Modulators and Method of Use EXELIXIS, INC. (US) 2011-01-27 — — US disclosed
US-20110021525-A1 P70S6 Kinase Modulators and Method of Use EXELIXIS, INC. (US) 2011-01-27 — — US disclosed
US-7816353-B2 P70S6 kinase modulators and method of use EXELIXIS, INC. (US) 2010-10-19 — — US disclosed
US-7816353-B2 P70S6 kinase modulators and method of use EXELIXIS, INC. (US) 2010-10-19 — — US disclosed
US-7816353-B2 P70S6 kinase modulators and method of use EXELIXIS, INC. (US) 2010-10-19 — — US disclosed
US-20070208020-A1 P70S6 Kinase Modulators And Method Of Use EXELIXIS, INC. 2007-09-06 — — US disclosed
US-20070208020-A1 P70S6 Kinase Modulators And Method Of Use EXELIXIS, INC. 2007-09-06 — — US disclosed
US-20070208020-A1 P70S6 Kinase Modulators And Method Of Use EXELIXIS, INC. 2007-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021525-A1 P70S6 Kinase Modulators and Method of Use EEF2K, RPS6KA3, MTOR MAPT 3812/4885LMNA 3817/4885KMT2A 3420/4885
US-20070208020-A1 P70S6 Kinase Modulators And Method Of Use EEF2K, RPS6KA3, MTOR MAPT 3812/4885LMNA 3817/4885KMT2A 3420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback